Abstract 231P
Background
Our research is focused on vitamin D3 active form calcitriol and its analog tacalcitol, and their interactions on the immune system, including Th17 lymphocytes, which plays a significant role in the development and progression of breast cancer. The aim was to analyze the direct effect of vitamin D compounds on its nuclear receptors in Th17 cells and changes in IL-17 production. The interaction with osteopontin (OPN) was examined as the example of indirect influence on Th17 cells population in breast cancer. Taking into account the hormonal status during disease development and stimulation of the immune system, we used mice: 6-8 weeks old as a premenopausal and 35-40 weeks old, ovariectomized, as a postmenopausal model. Our research was mainly focused on CD4+ lymphocytes isolated from spleens, looking forward to Th17 helper lymphocytes differentiation after treatment.
Methods
Animals bearing EMT6 or E0771 murine mammary gland cancer tumours were administered with calcitriol or tacalcitol from day 7 after inoculation, every three days, in the dose of 0.5 μg/kg or 1 μg/kg body weight/day, respectively. Local Ethics Committee permission No 50/2020. CD4+ cells (splenocytes) were isolated, cultured and examined for subpopulation phenotype, differentiation into Th17, gene expression profile, OPN impact on Th17 differentiation, expression of OPN receptors.
Results
Both compounds inhibited E0771 tumor growth, but tacalcitol increased metastasis in aged mice. The growth of EMT-6 tumors was stimulated in young and inhibited in aged mice after tacalcitol treatment. Metastasis was inhibited independently of the age by tacalcitol. In the E0771 premenopausal and EMT6 postmenopausal groups, tacalcitol increased the number of gene transcripts for IL17. The same tendency was observed in the E0771 postmenopausal group for the Il17 and Rorc genes. Blocking of selected CD4+ surface receptors (CD44, CD51), related to OPN functions, resulted in an increase of iTh17 cells after tacalcitol treatment. Tacalcitol in iTh17 cells induced the mRNA level for VDR, OPN, IL-21 and IL17R coding genes.
Conclusions
The Th17 induction via the OPN plays an important role, especially after tacalcitol treatment. Both compounds affect Th17 lymphocytes depending on the tumor type and age of mice.
Legal entity responsible for the study
The authors.
Funding
The National Science Center, OPUS 18 grant No. 2019/35/B/NZ5/01250.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
98P - Immuno-related cardiac toxicity: a prospective study applying multiparametric cardiac MRI
Presenter: Agnese Losurdo
Session: Poster Display session
99P - Real-world management of ir-colitis, a Danish 10-year cohort study
Presenter: Soeren Petersen
Session: Poster Display session
101P - Comparison on the effectiveness of multiple single and double immunotherapy treatments on advanced angiosarcoma patients: Meta analysis & systematic review
Presenter: Enzo Marson
Session: Poster Display session
Resources:
Abstract
102P - A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor
Presenter: Saifeng Li
Session: Poster Display session
103P - Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study
Presenter: zhihua wen
Session: Poster Display session
104P - The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) as second- or later-line therapy for metastatic non-small cell lung cancer
Presenter: Hualin Chen
Session: Poster Display session
105P - A retrospective study using machine learning to analyze the effects of VEGFR-TKIs and PD-1 inhibitors as third-line or later treatment in patients with MSS mCRC
Presenter: Shumei Han
Session: Poster Display session
Resources:
Abstract
106P - Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Presenter: Dimitrios Ziogas
Session: Poster Display session
107P - Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study
Presenter: Yulu Peng
Session: Poster Display session
Resources:
Abstract
108P - Transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab versus TACE alone in patients with Barcelona Clinic liver cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis
Presenter: Hongjie Cai
Session: Poster Display session
Resources:
Abstract